For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Laser Interstitial Thermal Therapy for Focal Cerebral Radiation Necrosis: A Case Report and Literature ReviewRahmathulla G.a · Recinos P.F.a, c · Valerio J.E.b · Chao S.a, d · Barnett G.H.a
aThe Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Department of Neurosurgery, Neurological and Taussig Cancer Institutes, Cleveland Clinic, Cleveland, Ohio, bDepartment of Neurosurgery, Cleveland Clinic, Weston, Fla., cDepartment of Neurosurgery, Johns Hopkins Hospital, Baltimore, Md., and dDepartment of Radiation Oncology, Neurological and Taussig Cancer Institutes, Cleveland, Ohio, USA Corresponding Author
Gene H. Barnett, MD
Department of Neurological Surgery – S73, The Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, OH 44195 (USA)
Tel. +1 216 444 8564, E-Mail email@example.com
Whole-brain radiotherapy and stereotactic radiosurgery (SRS) play a central role in the treatment of metastatic brain tumors. Radiation necrosis occurs in 5% of patients and can be very difficult to treat. The available treatment options for radiation necrosis include prolonged high-dose corticosteroids, hyperbaric oxygen, anticoagulation, bevacizumab, and surgical resection. We present the first report and results using laser-interstitial thermal therapy (LITT) for medically refractory radionecrosis. A 74-year-old diabetic patient who had a history of non-small cell lung cancer with brain metastases and subsequent treatment with SRS, presented with a focal lesion in the left centrum semiovale with progressively worsening edema. Image findings were consistent with radiation necrosis that was refractory despite prolonged, high-dose steroid therapy. His associated comorbidities obviated alternative interventions and the lesion was not in a location amenable to surgical resection. We used laser thermal ablation to treat the biopsy-proven radionecrosis. The procedure was tolerated well and the patient was discharged 48 hours postoperatively. Imaging at 7-week follow-up showed near complete resolution of the edema and associated mass effect. Additionally, the patient was completely weaned off steroids. To our knowledge this is the first report using LITT for the treatment of focal radiation necrosis. LITT may be an effective treatment modality for patients with medically refractory radiation necrosis with lesions not amenable to surgical decompression.
© 2012 S. Karger AG, Basel
Whole-brain radiation therapy, stereotactic radiotherapy, and stereotactic radiosurgery (SRS) are commonly used as part of multimodal treatment regimens to treat brain metastases . Radiation necrosis (RN) is the most common late side effect of radiation therapy, occurring in about 5% of treated patients. Cerebral RN usually develops between several months to as late as three years following treatment. It manifests clinically with focal neurological deficits or signs and symptoms of raised intracranial pressure .
The treatment of RN can include use of corticosteroids, surgical decompression of the lesion and its associated mass effect , and less commonly, therapeutic anticoagulation  and hyperbaric oxygen . Bevacizumab (BEV) is an anti-VEGF monoclonal antibody, which has shown promise in the treatment of radionecrosis  but has high costs, adverse effects, and long treatment durations. Patients with medically refractory RN who are not candidates to receive BEV or undergo surgery have been challenging to treat as their treatment options have been limited.
Various minimally invasive techniques are being used for treating ‘inoperable’ or difficult to access primary and secondary brain tumors. These include cryoablation , high-frequency ultrasound , radiofrequency ablation , and laser thermal ablation . Laser-interstitial thermal therapy (LITT) delivers focal laser energy selectively to coagulate tissue with interstitial hyperthermia and exhibits a sharp ablation boundary zone (based on the Arrhenius equation) . The boundary zone can be quantitatively and noninvasively detected using magnetic resonance (MR) thermometry . LITT was first used for tumor treatment by Bown in 1983  and for treatment of brain tumors by Sugiyama in 1990 . Subsequently, Ascher et al. , Roux et al. , and Kahn et al.  reported the use of LITT to treat surgically inaccessible metastases and glioblastomas. More recently Carpentier et al. [16,17] have used LITT to treat cases of resistant brain metastases based on clinical and radiological criteria, with good outcomes on long-term follow-up.
In this report, we used LITT to treat a patient with medically refractory RN in a region not amenable to surgical decompression. To our knowledge, this is the first report illustrating the use of LITT to successfully treat medically refractory, focal cerebral RN.
A 74-year-old right-handed, diabetic man with hypertension, renal dysfunction, and coronary artery disease requiring antiplatelet medication was diagnosed with non-small cell lung cancer with brain metastases. He was treated with radiation and chemotherapy for his lung cancer and SRS for the brain metastases in the left parietal and right frontal region, with each lesion receiving 20 Gy. One year later, a new intracranial lesion in the left centrum semiovale (adjacent to the previously treated left parietal lesion) measuring 4 mm in maximum diameter was treated with 20 Gy SRS (fig. 1). The SRS procedure was LINAC based using a multileaf collimator (mLC) with no other details of the procedure being available. Ten months following SRS, he presented with drooling, dysphasia, and slurred speech. Evaluation with magnetic resonance imaging (MRI) revealed that the centrum lesion had increased to 20 mm in maximum diameter. Additionally, there was significant perilesional edema and associated mass effect (fig. 2). A positron emission tomography-computed tomography (PET-CT) scan showed that the lesion was hypometabolic, and diffusion-weighted imaging (DWI) revealed restricted diffusion within the lesion, which was suggestive of radionecrosis.
With the clinical and radiological evidence in favor of radionecrosis, he was started on steroids to provide symptomatic relief and control the edema. He was treated for a period of 6 months with steroids; however, his symptoms did not resolve and his diabetes became poorly controlled. Medical treatment with BEV was avoided because of his associated systemic risk factors, namely use of antiplatelet medication, renal dysfunction, hypertension, and coronary artery disease. Other therapies were not deemed appropriate in this case due to lack of strong evidence supporting their use and the patient’s continued clinical deterioration. The associated medical comorbidities, surgical inaccessibility, and failure of steroid therapy made us opt for LITT as an option to treat the lesion.
For the procedure we used the AutoLITT® (Monteris Medical Inc., Winnipeg, Canada) system which has received FDA 510(k) clearance for clinical use in the United States since 2009 without specific limitation for intracranial use. The device consists of: (a) a fiber-optic laser probe, (b) patient-probe interface, (c) probe driver, and (d) MR trajectory planning and thermometry workstation. This integrates with non-Monteris devices including a head-fixation device, 1.5 Tesla (T) intraoperative MRI scanner, and a Dornier diode laser (1,064 nm), CO2-cooled, focused, pulse-sequence diode laser which emits a beam 90° orthogonal to the probe. The novel technologies in this device allow the laser probe to focus energy in one specific direction (perpendicular to its tip) rather than in the omnidirectional pattern of previously used bare fiber-optic laser probes. In addition, gaseous cooling is used to prevent heat dissipation to adjacent, nontargeted areas. The combination of focused energy delivery and gaseous cooling of the tip allows for conformal treatments. The probe, laser, and cooling are remotely controlled using real-time MR imaging and thermometry software.
Based on the temperatures reached within the lesion, three zones have been defined which can be visualized on the Monteris workstation while performing the procedure. Zone 1 is the region where maximal thermal damage has occurred, zone 2 is the outer limit of effective ablation, and zone 3 is where thermal changes occur without ablative effect (fig. 3). The goal of the procedure is to encompass the entire lesion within ablation zone 2 in order to be effective.
Under general anesthesia in the high-field (1.5 T) Intraoperative MR Suite (IMRIS™, Winnipeg, Canada), the patient was appropriately positioned. Trajectory planning was done using BrainLab iPlan® software (BrainLab™, Munich, Germany). The Stereotactic Miniframe (AXiiiS™, Winnipeg, Canada) was percutaneously fixed using image guidance (BrainLab™ VectorVision® Sky, Munich, Germany) locking the device to the tumor-intercept trajectory as planned by the surgeon. Using a drill guide, a 5-mm burr hole was then created along the trajectory. An MRI was done to confirm the intraoperative trajectory using the mobile MR scanner (fig. 4a). A stereotactic biopsy was performed prior to beginning the actual treatment. The biopsy revealed the presence of necrotic tissue without any evidence of tumor cells, consistent with radionecrosis. A 3-D model was used to confirm the trajectory and probe alignment, and calculate the appropriate length of the laser probe required to reach the target point (fig. 4b). Once the laser probe was in place, the ablation procedure began with the patient being in the isocenter of the MRI. Thermal ablation was started in the deepest portion of the lesion and gradually moved to the apex. The probe was manipulated axially and rotationally to focus the laser on different areas until the entire lesion was within zone 2. Once completed, the laser probe and stereotactic miniframe were removed, the burr hole and skin incision were closed in the usual fashion.
Once the appropriate thermal ablation zone was accomplished, an immediate series of MR sequences were obtained consisting of T1-weighted +/– contrast, T2-weighted, FLAIR, and diffusion sequences. Additional MRIs were obtained 24 hours after the procedure and at 7 weeks postoperatively.
The 24-hour postoperative MRI T1-weighted imaging revealed a central hyperintensity in the treatment location with faint peripheral contrast enhancement and T2/FLAIR prolongation within the lesion. The cross-sectional areas were used for objective calculations and obtained by the product of the largest perpendicular measurements in two places. Comparison of the preoperative and 24-hour postoperative scans showed no significant difference in the amount of surrounding edema. The 7-week T1 images revealed marginal increase in the diameter of the lesion, a minimal rim of enhancement, and markedly decreased edema on the T2 and FLAIR sequences (fig. 5).
Clinically the patient had word-finding difficulty and conduction dysphasia in the immediate postoperative period. These symptoms gradually improved and he was discharged 2 days following the procedure. His steroids were rapidly tapered off over 14 days, and he was closely followed for symptomatic worsening. On follow-up 7 weeks after the procedure, he remained neurologically stable, with near total resolution of symptoms and off of steroids.
The most significant late toxicity reported following SRS is cerebral RN, causing neurological complications in 2 to 32% of patients [18,19]. The characteristic findings associated with RN on imaging include: (a) an initial stabilization or decrease in lesion size 3–6 months post SRS, (b) a subsequent increase in contrast enhancement in the treated area on T1 images with significant perilesional edema, and (c) lack of flow through the lesion on perfusion MR sequences . The variables associated with development of RN include radiation dose, volume of the tumor treated, and tumor location . Typically RN develops between 1 and 3 years following treatment.
Blood-brain barrier (BBB) dysfunction and radiation-induced damage to the microglia and astrocytes play a central role in the pathophysiology of RN and edema development . BBB dysfunction occurs secondary to delayed parenchymal loss, incomplete restoration of vascular endothelial cells lining the BBB , and vascular endothelial cell apoptosis . This is followed by release of cytokines, upregulation of VEGF, and overexpression of intracellular adhesion molecule-1. Specifically, VEGF has two biological properties that contribute to the disruption of the BBB and propagation of RN: it induces angiogenesis and it increases vascular permeability [25,26]. Vasogenic edema ensues once the BBB is disrupted and causes further hypoxia. Cellular necrosis ensues as a result of hypoxia and results in release of HIF-1α  secondary to the upregulation of VEGF. Histopathologically proliferating endothelial cells show weak immunoreactivity for VEGF, compared to the perinecrotic zone of astrocytes, which has high staining for VEGF. Endothelial cell proliferation appears to be strongly stimulated by VEGF produced in the perinecrotic zones, this phenomenon is easily observed in the analysis of brain specimens of patients with RN who were treated for head and neck cancers, where there are no intracranial tumor cells which could confound the results . Telangiectasias and capillary collapse with hyalinization of vessels and fibrinoid necrosis-associated changes are seen in RN as well [29,30]. Radiation-induced damage to microglia and astrocytes in the perinecrotic zone produces large amounts of VEGF and a delayed peak in the release of TNF-α , which leads to a cycle of further cell death, perpetuates the release of inflammatory factors, and increases BBB disruption.
Medical treatment of cerebral RN has focused on controlling the vasogenic edema that results from BBB disruption. Steroids are the first-line therapy and can bring about significant symptomatic improvement as well as timely control of cerebral edema . However, therapy can be prolonged and increasing doses may be required to bring about a therapeutic effect. Increasing steroid doses are also associated with numerous medical complications, such as hyperglycemia and increased risk of infection. BEV, a monoclonal antibody directed against VEGF, has recently been evaluated to treat RN . Notable improvements have been observed in the clinical status and imaging in patients treated with BEV, adding another medical option in the treatment of these lesions [4,32]. However, BEV is not appropriate for all patients given its side-effect profile.
Several alternative therapies have been proposed to treat RN. Rizzoli and Pagnanelli  reported a dramatic improvement of 2 patients with RN while on anticoagulant (warfarin) therapy. Subsequently, Glantz et al.  reported their results treating 8 patients with RN, using heparin and warfarin. More recently Happold et al.  reported the use of anticoagulation for 7 patients with heterogeneous lesions. Three out of 7 patients had cranial radionecrosis lesions and had modest improvement. Although Rizzoli and Pagnanelli  and Glantz et al.  reported good outcomes, their cohort of patients was small and follow-up time short, with no clear details of associated steroid use at the time of treatment. Pentoxifylline (PTX) was also been evaluated to treat RN. PTX is a methylxanthine derivative that increases blood cell deformity and decreases viscosity, thus enhancing circulation. Dion et al.  reported the preliminary results of PTX contributing to wound healing following radiation injury. A combination of vitamin E or tocopherol along with PTX was shown to reduce radiation-induced fibrosis of the skin , as well as early and late radiation adverse effects in patients treated for lung and breast cancer [38,39,40]. Vitamin E acts as a scavenger for free radicals released and protects cell membranes and may potentiate the benefits of PTX in the treatment of RN. Williamson et al.  studied the effects of the combination of vitamin E and PTX in their cohort of 11 patients with RN and concluded that the therapy may have beneficial effects. The study was limited by the concomitant use of steroids, and the heterogeneous population of patients. Along with PTX, aspirin and ticlopidine have been used, on the premise that vascular occlusive changes associated with radionecrosis may improve with antiplatelet medication. Most reports, however, are anecdotal, and since many of these patients have also received steroids concurrently, it is difficult to conclude whether the steroids, PTX, or natural history invariably led to resolution of symptoms [41,42].
Hyperbaric oxygen (HBO) has been reported to have a beneficial effect in treating delayed radiation injury of tissues such as the rectum, head and neck, and mandible . Hypoxia is a potent inducer of HIF-1α which in turn releases other cytokines and intracellular adhesion molecule-1, which potentiate BBB breakdown . By increasing tissue oxygenation, HBO may inhibit HIF-1α induction and release, preventing the subsequent cascade and release of factors responsible for propagating the cycle of RN. Clinically, Hart and Mainous  first used HBO more than 30 years ago to treat 69 patients with various forms of radiation-induced injury. Various others have since reported their experience with the use of HBO in RN [5,46,47,48]. Because of the retrospective nature of data collection, and a majority of patients having received varying doses of concurrent steroids, evidence to support the use of HBO in radionecrosis remains weak .
The utilization of heat in cancer therapy is not a new concept, with radiofrequency, microwaves and ultrasound all being used to treat brain tumors [49,50,51]. The difficulty has remained controlling the distribution of hyperthermia within the target tissue, thus avoiding damage to normal brain parenchyma. This makes interstitial thermotherapy an ideal choice because of improved localization and dispersal within target tissue . Interstitial thermotherapy is minimally invasive and mainly used to treat deep-seated, primarily inoperable brain tumors . Various clinical studies conducted using different devices have all shown responses ranging from remission to shrinking tumor sizes as well as prolonged survival as assessed by clinical and imaging follow-up [54,55]. The limitations with the initial probes using Nd:YAG lasers were because of their inability to control penetration depths, susceptibility to char, and uncertainty of extent of coagulation resulting in risk to adjacent normal tissues . Using real-time MR imaging and thermometry during the procedure, accurate temperature measurements within the targeted lesion as well as adjacent cerebral structures can be accurately calculated, thus limiting any unnecessary thermal damage to nonlesional cortex.
Intraoperative detection of the perinecrotic or gliotic zone in RN has been performed and reported using fluorescence of protoporphyrin IX , with surgical resection of this zone demonstrating rapid improvements both radiologically and clinically . Our hypothesis in using LITT to treat cerebral RN was to replace the endothelial proliferating cells and zone of disorganized angiogenesis with thrombosed vessels. The perinecrotic zone (gliotic) zone was also targeted in the treatment volume, and real-time thermal isodose contours confirmed complete ablative treatment of the predefined target region (which included the necrotic center, contrast-enhancing periphery and the perinecrotic/gliotic zone for which we included a margin of about 0.5 cm all around the target lesion). Functionally, the perinecrotic zone is responsible for much of the VEGF release, which is a potent angiogenic peptide and cause of vasogenic edema, causing further release of HIF-1α and ICAM-1 activation as well. By targeting this gliotic zone with LITT, the dysfunctional astrocytes and endothelial cells undergo coagulative necrosis effectively removing most of the source of active VEGF.
In this case, there were several clinical factors that led us to use LITT: (1) prolonged steroid therapy had not resulted in clinical improvement and destabilized the patient’s diabetes, (2) the lesion was located in the centrum semiovale and was deep-seated which we felt could not be safely resected via open cranial surgery without causing neurological deficits, (3) the patient’s comorbidities and antiplatelet therapy prevented the use of BEV, and (4) the progressively worsening symptoms warranted urgent intervention. We used the AutoLITT® device because of the advantages this treatment system has for laser thermal ablation of lesions; namely (a) the laser fires from within the tumor, (b) the surgeon has control over the direction, depth, and duration of fire, (c) thermal damage ceases virtually immediately when the laser is shut off, limiting tissue death to the tumor and avoiding unwanted damage to nearby healthy tissue and structures, and (d) thermal damage threshold lines accurately predict the extent of tissue coagulation. The first-in-man trials using the AutoLITT® device (Monteris medical) in the setting of recurrent glioblastoma were completed in 2009 with results revealing a significantly improved median survival in the treated group [manuscript in preparation].
Various studies have reported early and late MRI findings in patients undergoing LITT for brain tumors . Acute lesions consisted of reverse signal intensities on T1- and T2-weighted imaging, with a high signal in the center of the lesion, and low signal intensities in the periphery on T1 sequences. Late (mean 93 days) imaging revealed a reduction in lesion size with an enhancing rim that persisted for a long duration. In this case, the patient had early symptomatic improvement, was able to be completely weaned off of steroids, and had marked reduction of edema, which provides evidence that the treatment was effective. Although 7-week postoperative imaging showed an increase in lesion size, it is possible that this is consistent with the natural course after LITT therapy as seen in tumors treated with LITT .
There are several limitations to this study. First, it is a single case that demonstrates that it is feasible to treat RN with LITT and is suggestive of a treatment effect. A prospective study with a larger number of patients with medically refractory RN would need to be performed to further evaluate the efficacy of LITT to treat RN. Second, stereotactic tissue biopsy is required to obtain a diagnosis. Given that the diagnostic yield ranges between 80–96%, the possibility of a mixed lesion cannot be discounted [59,60]. We did use PET-CT which has a sensitivity of 86% and specificity of 80% as an initial investigation for diagnosing RN in this case . In addition, biopsies from the gliotic zone with immunostaining before and after the procedure may increase diagnostic yield; however, the risk of multiple entries and biopsy sites may not be justified.
LITT is a safe technique for treating focal cerebral radionecrosis, with good control of cerebral edema along with clinical improvement evident on short (7-week) follow-up. LITT may be an effective option for medically refractory radionecrosis that is not amenable to surgical decompression. Its effect in radiation-induced injury needs to be studied further.
The authors wish to thank Ms. Christine Moore and Ms. Martha Tobin for their assistance with the preparation of the manuscript.
Gene H. Barnett, MD
Department of Neurological Surgery – S73, The Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, OH 44195 (USA)
Tel. +1 216 444 8564, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.